Scarica l'app Stockscreener
19.00
4.85%
-0.95
Precedente Chiudi:
$19.95
Aprire:
$19.76
Volume 24 ore:
748.26K
Relative Volume:
0.25
Capitalizzazione di mercato:
$1.20B
Reddito:
$16.10M
Utile/perdita netta:
$-198.97M
Rapporto P/E:
-5.4584
EPS:
-3.4809
Flusso di cassa netto:
$-183.99M
1 W Prestazione:
+5.28%
1M Prestazione:
+12.39%
6M Prestazione:
-71.96%
1 anno Prestazione:
+26.55%
Intervallo 1D:
$18.66
$20.44
Intervallo di 1 settimana:
$16.60
$20.91
Portata 52W:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Nome
Uniqure Nv
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
19.00 | 1.14B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
424.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
703.70 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.92 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.38 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
292.86 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure Nv Borsa (QURE) Ultime notizie
uniQure (QURE) Shares Surge 22% on Positive Regulatory News for AMT-130 - GuruFocus
uniQure stock rises after regulatory updates (QURE:NASDAQ) - Seeking Alpha
UniQure Plans to Submit UK Marketing Authorization Application for Huntington's Disease Treatment - marketscreener.com
uniQure plans UK filing for Huntington’s gene therapy AMT-130 By Investing.com - Investing.com India
uniQure meets with UK MHRA on AMT-130 for Huntington’s disease - The Pharma Letter
Aberdeen Group (QURE) reports 5.31M shares, 8.49% stake | Schedule 13G/A - Stock Titan
uniQure advances AMT-130 toward UK marketing approval - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
uniQure plans UK filing for Huntington’s gene therapy AMT-130 - Investing.com
AMT-130 Huntington’s gene therapy nears UK filing for uniQure (NASDAQ: QURE) - Stock Titan
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease - GlobeNewswire
Earnings Preview: UniQure NV to Report Financial Results Pre-market on May 05 - 富途牛牛
QURE stock crashes 32% in a week: Here's what you should know - MSN
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
UniQure used 'distorted comparison' in Huntington's asset trial: FDA official - MSN
UniQure surges following departure of key FDA official - MSN
Before the bell, uniQure posts Q1 numbers and takes questions May 5 - Stock Titan
uniQure to Announce First Quarter 2026 Financial Results - Sahm
uniQure NV (MEX:QUREN) Stock Earnings Transcripts - GuruFocus
uniQure (NASDAQ: QURE) outlines 2026 proxy agenda, equity and charter changes - Stock Titan
[ARS] uniQure N.V. SEC Filing - Stock Titan
(QURE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
uniQure announces $200 million proposed public offering - MSN
QURE Forecast, Price Target & Analyst Ratings | UNIQURE NV (NASDAQ:QURE) - ChartMill
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data (PR Newswire) - Aktiellt
uniQure N.V. (QURE) Stock Outlook | Q4 2025: Profit Exceeds ViewsROCE - Xã Châu Thành
uniQure N.V. (QURE) Stock Posts 30% Growth from Last Year - Insider Monkey
QURE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
uniQure NV (MEX:QUREN) Short-term investments - GuruFocus
Barclays reaffirms equal weight rating for uniQure (QURE) - MSN
uniQure Shares Collapse 75% After FDA Reverses Position on Huntington’s Therapy - MSN
QURE Maintained by Goldman Sachs -- Price Target Raised to $10.0 - GuruFocus
uniQure N.V. (QURE) Stock: Fair Value Assessment (Extends Gains) 2026-04-20Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
uniQure N.V. (QURE) Stock Virtual Order (+4.58%) 2026-04-18Community Volume Signals - Cổng thông tin điện tử Tỉnh Sơn La
uniQure NV Stock Operating Data - GuruFocus
uniQure NV (MEX:QUREN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
uniQure NV (MEX:QUREN) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Q4 2025 Uniqure NV Earnings Call Transcript - GuruFocus
uniQure NV (MEX:QUREN) Stock Price & 30 Year Financial Data - GuruFocus
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
Total debt per share of uniQure N.V. – SWB:UQ1 - TradingView
uniQure N.V. (NASDAQ:QURE) Sees Significant Decrease in Short Interest - MarketBeat
UniQure NV (NASDAQ:QURE) Q4 2025 earnings call transcript - MSN
uniQure N.V. (QURE) Stock Analysis: Navigating a 129.74% Potential Upside in Biotechnology - DirectorsTalk Interviews
uniQure (Nasdaq: QURE) requests 12.4M-share delegation, 10% buyback - Stock Titan
(QURE) Risk Channels and Responsive Allocation - Stock Traders Daily
UniQure shares surge 26% on US FDA shakeup even as momentum tumbles: Will new leadership greenlight Huntington's therapy? - MSN
uniQure (NASDAQ:QURE) Trading Down 3.7%Here's What Happened - MarketBeat
Early UniQure Fabry trial shows lasting enzyme boost, safety watch - MSN
Uniqure Nv Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure Nv Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '26 |
Sale |
9.06 |
808 |
7,320 |
189,669 |
| Potts Jeannette | Chief Legal Officer |
Mar 04 '26 |
Sale |
9.06 |
3,412 |
30,913 |
138,483 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '26 |
Sale |
9.06 |
12,000 |
108,720 |
226,581 |
0.00%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):